ABSTRACT
Considerable advances have been made in catalytic methodologies to perform asymmetric oxidations.Although no large-scale processes for commercial pharmaceuticals currently use the technology, the methods are relatively new compared with catalytic asymmetric hydrogenation. However, the approach is now in the synthetic arsenal and it is surely just a matter of time before it comes to fruition.
